Agencies, 22 September: Dr Reddy’s Laboratories Ltd para Russia’s potential coronavirus vaccine nemide late-stage Indian clinical trials toh anibole olob hapta te suru koribo pari. Etu khobor toh Tuesday te Indian drugmaker laga executive para janaideya laga ase.
India para trials toh Sputnik-V vaccine candidate te lobole ase. Etu toh Russia laga sovereign wealth fund para bona (develop) laga ase. India para etu trials nemide 1,000-2,000 volunteers ke register koribo aro etu toh desh laga alak alak government aro private hospitals te lobo. Etu kobor toh Dr. Reddy laga API aro pharmaceutical services nemide CEO, Deepak Sapra para janaideya laga ase.
Sapra para tai khan laga first step toh aha hapta pithor te clinicl trials suru koribole nemide Indian regulators para lakiya approvals pabole nemide ase koise.
Trials toh Russian Direct Investment Fund (RDIF) aro Dr Reddy’s majode ekta deal laga part hisaab te ase. Etu nemide Indian firm para India te Phase III studies lobole ase aro etu toh lakiya approval powa bechide. RDIF para Dr Reddy’s ke 100 million doses supply koribole ase.
RDIF be India te 300 million doses laga shot olabo (produce) nemide Indian manufacturers logode agreements korise. Russia toh novel coronavirus v accine nemide regulatory approval powa first desh thakise.
Sapra para India te Sputnik-V doses supplied toh India aro Russian-made doses mela nesana hobo koise. Tai para be India te RDIF aro Dr Reddy’s para joldi potential manufacturers identify koribo koise.
Add Comment